The Pathophysiology and Treatment of Hereditary Tyrosinemia Type 1

Purified hematopoietic stem cells can differentiate into hepatocytes in vivo

Lagasse, E., Connors, H., Al-Dhalimy, M., Reitsma, M., Dohse, M., Osborne, L., Wang, X., Finegold, M., Weissman, I. L., & Grompe, M. (2000) · Nature Medicine · doi:10.1038/81326 · Cited by 2,314

Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis

Nebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., & Dalton, T. P. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00310-x · Cited by 1,008

THE INCIDENCE OF ALKAPTONURIA : A STUDY IN CHEMICAL INDIVIDUALITY.

Garrod, A. (1902) · The Lancet · doi:10.1016/s0140-6736(01)41972-6 · Cited by 800

Mammalian Genes Coordinately Regulated by Growth Arrest Signals and DNA-Damaging Agents

Fornace, A. J., Nebert, D. W., Hollander, M. C., Luethy, J. D., Papathanasiou, M., Fargnoli, J., & Holbrook, N. J. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.10.4196 · Cited by 694

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631

Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes.

Overturf, K., Al-Dhalimy, M., Ou, C. N., Finegold, M. J., & Grompe, M. (1997) · Europe PMC (PubMed Central) · Cited by 599

Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I

Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549

On the enzymic defects in hereditary tyrosinemia.

Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447

Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice

Grompe, M., al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. G., & Soriano, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2298 · Cited by 355

THE NATURE OF THE DEFECT IN TYROSINE METABOLISM IN ALCAPTONURIA

Du, B. N. L., Zannoni, V. G., Laster, L., & Seegmiller, J. E. (1958) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70560-7 · Cited by 353

The molecular basis of alkaptonuria

Fernández-Cañón, J. M., Granadino, B., de Bernabé, D. B.-V., Renedo, M., Fernández‐Ruiz, E., Peñalva, M. A., & de Córdoba, S. R. (1996) · Nature Genetics · doi:10.1038/ng0996-19 · Cited by 327

Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I

Grompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312

Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264

Neurologic Crises in Hereditary Tyrosinemia

Mitchell, G. A., Larochelle, J., Lambert, M. A., Michaud, J., Grenier, A., de Baulny, H. O., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 230

Genetic control of morphogenetic and biochemical differentiation: Lethal albino deletions in the mouse

Gluecksohn-Waelsch, S. (1979) · Cell · doi:10.1016/0092-8674(79)90001-1 · Cited by 218

The Repopulation Potential of Hepatocyte Populations Differing in Size and Prior Mitotic Expansion

Overturf, K., Al-Dhalimy, M., Finegold, M. J., & Grompe, M. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65531-9 · Cited by 202

Characterization of a Fungal Maleylacetoacetate Isomerase Gene and Identification of Its Human Homologue

Fernández-Cañón, J. M., & Peñalva, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.329 · Cited by 183

Self-induced correction of the genetic defect in tyrosinemia type I.

Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168

Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.

(1990) · Europe PMC (PubMed Central) · Cited by 163

Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes

Ruppert, S., Boshart, M., Bosch, F. X., Schmid, W., Fournier, R. E. K., & Schütz, G. (1990) · Cell · doi:10.1016/0092-8674(90)90200-x · Cited by 139

A Single Mutation of the Fumarylacetoacetate Hydrolase Gene in French Canadians with Hereditary Tyrosinemia Type I

Grompe, M., St.-Louis, M., Demers, S. I., Al-Dhalimy, M., Leclerc, B., & Tanguay, R. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310603 · Cited by 135

Molecular Characterization of a Gene Encoding a Homogentisate Dioxygenase from Aspergillus nidulans and Identification of Its Human and Plant Homologues

Fernández-Cañón, J. M., & Peñalva, M. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.21199 · Cited by 135

The Mutagenicity of the Tyrosine Metabolite, Fumarylacetoacetate, Is Enhanced by Glutathione Depletion

Jorquera, R., & Tanguay, R. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6220 · Cited by 117

Liver Repopulation and Correction of Metabolic Liver Disease by Transplanted Adult Mouse Pancreatic Cells

Wang, X., Al-Dhalimy, M., Lagasse, E., Finegold, M. J., & Grompe, M. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63999-5 · Cited by 117

Hereditary tyrosinemia type I--an overview.

Kvittingen, E. A. (1986) · PubMed · Cited by 109

From toxicological problem to therapeutic use: The discovery of the mode of action of 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC), its toxicology and development as a drug

Lock, E. A., Ellis, M. K., Gaskin, P., Robinson, M., Auton, T. R., Provan, W. M., Smith, L. L., Prisbylla, M. P., Mutter, L. C., & Lee, D. L. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005458703363 · Cited by 109

Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect

Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102

Principles of Therapeutic Liver Repopulation

Grompe, M., Laconi, E., & Shafritz, D. A. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007093 · Cited by 97

Visceral pathology of hereditary tyrosinemia type I.

Russo, P., & O’Regan, S. (1990) · Europe PMC (PubMed Central) · Cited by 94

HOMOGENTISATE OXIDASE OF LIVER

Knox, W. E., & Edwards, S. W. (1955) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)81406-0 · Cited by 93

A Defect in the Metabolism of Aromatic Amino Acids in Premature Infants: The Role of Vitamin C

LEVINE, S. Z., Marples, E., & Gordon, H. H. (1939) · Science · doi:10.1126/science.90.2348.620 · Cited by 89

HOMOGENTISATE METABOLISM: THE ISOMERIZATION OF MALEYLACETOACETATE BY AN ENZYME WHICH REQUIRES GLUTATHIONE

Edwards, S. W., & Knox, W. E. (1956) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65334-7 · Cited by 81

Crystal structure and mechanism of a carbon–carbon bond hydrolase

Timm, D. E., Mueller, H. A., Bhanumoorthy, P., Harp, J. M., & Bunick, G. J. (1999) · Structure · doi:10.1016/s0969-2126(99)80170-1 · Cited by 81

Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors

Kubo, S., Sun, M., Miyahara, M., Umeyama, K., Urakami, K.-I., Yamamoto, T., Jakobs, C., Matsuda, I., & Endo, F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9552 · Cited by 77

Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I

Overturf, K., Al-Dhalimy, M., Ou, C., Finegold, M. J., Tanguay, R. M., Lieber, A., Kay, M. A., & Grompe, M. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.5-513 · Cited by 77

Ex Vivo Hepatic Gene Therapy of a Mouse Model of Hereditary Tyrosinemia Type I

Overturf, K., Al-Dhalimy, M., Manning, K., Ou, C., Finegold, M. J., & Grompe, M. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.3-295 · Cited by 72

Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity

Labelle, Y., Phaneuf, D., Leclerc, B., & M.Tanguay, R. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.941 · Cited by 67

Fungal metabolic model for human type I hereditary tyrosinaemia.

Fernández-Cañón, J. M., & Peñalva, M. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9132 · Cited by 65

Mechanistic Inferences from the Crystal Structure of Fumarylacetoacetate Hydrolase with a Bound Phosphorus-based Inhibitor

Bateman, R. L., Bhanumoorthy, P., Witte, J. F., McClard, R. W., Grompe, M., & Timm, D. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007621200 · Cited by 62

Cyclin B‐dependent kinase and caspase‐1 activation precedes mitochondrial dysfunction in fumarylacetoacetate‐induced apoptosis

Jorquera, R., & Tanguay, R. M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.15.2284 · Cited by 61

Interaction between the Ah receptor and proteins binding to the AP-1-like electrophile response element (EpRE) during murine phase II [Ah] battery gene expression

Vasiliou, V., Puga, A., Chang, C., Tabor, M. W., & Nebert, D. W. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02108-6 · Cited by 61

Deletions near the albino locus on chromosome 7 of the mouse affect the level of tyrosine aminotransferase mRNA.

Schmid, W., Müller, G., Schütz, G., & Gluecksohn‐Waelsch, S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.9.2866 · Cited by 57

Different Clinical Forms of Hereditary Tyrosinemia (Type I) in Patients with Identical Genotypes

Poudrier, J., Lettre, F., Scriver, C. R., Larochelle, J., & Tanguay, R. M. (1998) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1998.2695 · Cited by 55

Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report

Grompe, M., Overturf, K., Al-Dhalimy, M., & Finegold, M. J. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005462804271 · Cited by 54

Liver repopulation for the treatment of metabolic diseases

Grompe, M. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1010375203539 · Cited by 54

Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I

St-Louis, M., Leclerc, B., Laine, J., K.Salo, M., Holmberg, C., & Tanguay, R. M. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.1.69 · Cited by 50

Trans regulation of the phosphoenolpyruvate carboxykinase (GTP) gene, identified by deletions in chromosome 7 of the mouse.

Loose, D. S., Shaw, P. A., Krauter, K. S., Robinson, C. A., Englard, S., Hanson, R. W., & Gluecksohn‐Waelsch, S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5184 · Cited by 50

In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I

Manning, K., Al-Dhalimy, M., Finegold, M. J., & Grompe, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.11928 · Cited by 50

Chronic Tyrosinemia Associated with 4-Hydroxyphenylpyruvate Dioxygenase Deficiency with Acute Intermittent Ataxia and without Visceral and Bone Involvement

Giardini, O., Cantani, A., Kennaway, N. G., & D’Eufemia, P. (1983) · Pediatric Research · doi:10.1203/00006450-198301000-00005 · Cited by 47

Tyrosinemia Type 1 Should Be Suspected in Infants With Severe Coagulopathy Even in the Absence of Other Signs of Liver Failure

Croffie, J. M. B., Gupta, S. K., Chong, S. K. F., & Fitzgerald, J. F. (1999) · PEDIATRICS · doi:10.1542/peds.103.3.675 · Cited by 46

[38] Enzymes involved in conversion of tyrosine to acetoacetate

Knox, W. E. (1955) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(55)02202-7 · Cited by 45

Richner-Hanhart syndrome (tyrosinaemia-II) (report of four cases without ocular involvement)

Rehák, A., Selim, M. M., & YADAV, G. (1981) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1981.tb15320.x · Cited by 45

Tyrosinemia type III: diagnosis and ten‐year follow‐up

Cerone, R., Holme, E., Schiaffino, M., Caruso, U., Maritano, L., & Romano, C. (1997) · Acta Paediatrica · doi:10.1111/j.1651-2227.1997.tb15192.x · Cited by 44

A Mouse Model of Renal Tubular Injury of Tyrosinemia Type 1

SUN, M.-S., Hattori, S., Kubo, S., Awata, H., Matsuda, I., & Endo, F. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v112291 · Cited by 40

Marked increases in hepatic NAD(P)H:oxidoreductase gene transcription and mRNA levels correlated with a mouse chromosome 7 deletion.

Petersen, D. D., Gonzalez, F. J., Rapić, V., Kozak, C. A., Jong‐Youn, L. E. E., Jones, J. E., & Nebert, D. W. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6699 · Cited by 38

In Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral Vectors

Chen, S. J., Tazelaar, J., Moscioni, A. D., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0065 · Cited by 35

The Richner-Hanhart Syndrome

Bienfang, D. C. (1976) · Archives of Ophthalmology · doi:10.1001/archopht.1976.03910040045009 · Cited by 30

Resolution of the clinical features of tyrosinemia following orthotopic liver transplantation for hepatoma

Thiel, D. H. V., Gartner, L. M., Thorp, F. K., Newman, S. L., Lindahl, J. A., Stoner, E., New, M. I., & Starzl, T. E. (1986) · Journal of Hepatology · doi:10.1016/s0168-8278(86)80144-1 · Cited by 30

Prenatal Diagnosis of Hereditary Tyrosinemia by Determination of Fumarylacetoacetase in Cultured Amniotic Fluid Cells

Kvittingen, E. A., Steinmann, B. U., GITZELMANN, R., Leonard, J. V., Andria, G., Børresen‐Dale, A., Mossman, J., Micara, G., & LINDBLAD, B. (1985) · Pediatric Research · doi:10.1203/00006450-198519040-00002 · Cited by 28

Molecular mapping of albino deletions associated with early embryonic lethality in the mouse

Niswander, L., Kelsey^, G., Schedl, A., Ruppert, S., Sharan, S. K., Holdener-Kenny, B., Rinchik, E. M., Edström, J.-E., & Magnuson, T. (1991) · Genomics · doi:10.1016/0888-7543(91)90234-6 · Cited by 28

Effects of succinylacetone on the uptake of sugars and amino acids by brush border vesicles

Spencer, P. D., Medow, M. S., Moses, L. C., & Roth, K. S. (1988) · Kidney International · doi:10.1038/ki.1988.231 · Cited by 24

Screening for tyrosinaemia type I.

Hutchesson, A. C. J., Hall, S. K., Preece, M. A., & Green, A. (1996) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.74.3.f191 · Cited by 24

Presentation of the Data of the Italian Registry for Oculocutaneous Tyrosinaemia

Fois, A., Borgogni, P., Cioni, M., Molinelli, M., Frezzotti, R., Bardelli, A. M., Lasorella, G., Barberi, L., Durand, P., Rocco, M. D., et al. (1986) · Springer eBooks · doi:10.1007/978-94-009-4131-1_42 · Cited by 23

Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis.

Demers, S. I., Phaneuf, D., & Tanguay, R. M. (1994) · PubMed Central · Cited by 22

Liver transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma.

Esquivel, C. O., Mieles, L., Marino, I. R., Todo, S., Makowka, L., Ambrosino, G., Nakazato, P. Z., & Starzl, T. E. (1989) · PubMed · Cited by 20

Inherited Hepatic Enzyme Defects as Candidates for Liver-Directed Gene Therapy

Horwich, A. L. (1991) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-76015-0_9 · Cited by 19

A lethal deletion on mouse chromosome 7 affects regulation of liver-cell-specific functions: posttranscriptional control of serum protein and transcriptional control of aldolase B synthesis.

Sala-Trepat, J. M., Poiret, M., Sellem, C. H., Bessada, R., Erdös, T., & Gluecksohn‐Waelsch, S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.8.2442 · Cited by 19

The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency

Rootwelt, H., Kvittingen, E. A., Høie, K., Agsteribbe, E., Hartog, M., van Faassen, H., & Berger, R. (1992) · Human Genetics · doi:10.1007/bf00217128 · Cited by 17

First‐trimester prenatal diagnosis of tyrosinemia type I by amniotic fluid succinylacetone determination

Jakobs, C., Stellaard, F., Kvittingen, E. A., Henderson, M. J., & Lilford, R. J. (1990) · Prenatal Diagnosis · doi:10.1002/pd.1970100210 · Cited by 16

Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of delta-aminolevulinate synthase in liver.

Sassa, S., & Kappas, A. (1982) · PubMed · Cited by 15

A CASE OF TYROSINAEMIA TYPE I WITH NORMAL LEVEL OF SUCCINYLACETONE IN THE AMNIOTIC FLUID

Grenier, A., Cederbaum, S. D., Laberge, C. M., GAGNÉ, R., Jakobs, C., & Tanguay, R. M. (1996) · Prenatal Diagnosis · doi:10.1002/(sici)1097-0223(199603)16:3 · Cited by 13

Effects of succinylacetone on amino acid uptake in the rat kidney

Spencer, P. D., & Roth, K. S. (1987) · Biochemical Medicine and Metabolic Biology · doi:10.1016/0885-4505(87)90015-6 · Cited by 13

Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1

Bain, M. D., Purkiss, P., Jones, M. A., Bingham, P. J., Stacey, T. E., & CHALMERS, R. A. (1990) · European Journal of Pediatrics · doi:10.1007/bf02034752 · Cited by 12

Liver transplantation in type I tyrosinemia.

Pascual, F. J. M., Vázquez, J., Gámez, M., López Santamaría, M., de la Vega, A., Mc, D., Jara, P., & Tovar, J. A. (1995) · PubMed · Cited by 8

Mspl RFLP in the human fumarylacetoacetate hydrolase (FAH) gene

Demers, S. I., & Tanguay, R. M. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.24.6971 · Cited by 6

Putative genetic deficiency of 4‐hydroxyphenylpyruvic acid dioxygenase in mice: A murine model for hereditary tyrosinaemia type III

Endo, F., Katoh, H., & Matsuda, I. (1990) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01799587 · Cited by 5

Sural nerve lesions in a case of hypertyrosinemia

Origuchi, Y., Endo, F., Kitano, A., Nagata, N., & Matsuda, I. (1982) · Brain and Development · doi:10.1016/s0387-7604(82)80074-0 · Cited by 5

[A system of early screening for inborn errors of metabolism: methods and results for hereditary tyrosinemia].

Bélanger, M., Saint-Hilaire, B., & Bélanger, L. (1973) · PubMed · Cited by 1

Acute liver failure

Lee, W. M., Squires, R. H., Nyberg, S. L., Doo, E. C., & Hoofnagle, J. H. (2008) · Hepatology · doi:10.1002/hep.22177 · Cited by 769

Altered metabolite levels in cancer: implications for tumour biology and cancer therapy

Sullivan, L. B., Gui, D. Y., & Heiden, M. G. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.85 · Cited by 406

The Homogentisate Pathway: a Central Catabolic Pathway Involved in the Degradation of l -Phenylalanine, l -Tyrosine, and 3-Hydroxyphenylacetate in Pseudomonas putida

Arias‐Barrau, E., Olivera, E. R., Luengo, J. M., Fernández, C., Galán, B., García, J. L., Díaz, E., & Miñambres, B. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.15.5062-5077.2004 · Cited by 266

Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations

Chinsky, J. M., Singh, R., Ficicioglu, C., van Karnebeek, C. D. M., Grompe, M., Mitchell, G., Waisbren, S. E., Gucsavas-Calikoglu, M., Wasserstein, M. P., Coakley, K., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.101 · Cited by 247

A journey of hope: lessons learned from studies on rare diseases and orphan drugs

Wästfelt, M., Fadeel, B., & Henter, J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01666.x · Cited by 184

Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1

Morrow, G., & Tanguay, R. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_2 · Cited by 72

Hereditary Tyrosinemia

Halvorsen, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9 · Cited by 11

Hereditary Tyrosinemia Type 1 in Turkey

Zeybek, A. Ç. A., Kıykım, E., & Cansever, M. Ş. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_15 · Cited by 12

Diagnosis and management of tyrosinemia type I

Holme, E., & Lindstedt, S. (1995) · The Journal of Pediatrics · doi:10.1097/00008480-199512000-00017 · Cited by 65

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype

Neuckermans, J., Lequeue, S., Claes, P., Heymans, A., Hughes, J. H., Colemonts‐Vroninks, H., Marcélis, L., Casimir, G. J., Goyens, P. J., Martens, G. A., et al. (2023) · Genes · doi:10.3390/genes14030693 · Cited by 10